Zymeworks Inc. (ZYME)
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Phase 3 data for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, a much larger opportunity. Partnerships with Jazz and BeiGene provide non-dilutive funding and milestone payments, but limit Zymeworks' upside to royalties and milestones.
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore - Chief Scientific Officer Leone Patterson - Executive Vice President, Chief Business and Financial Officer Conference Call Participants Charles Zhu - LifeSci Capital Brian Cheng - JPM Stephen Willey - Stifel Jonathan Miller - Evercore ISI Amanda Acosta-Ruiz - Leerink Partners Yigal Nochomovitz - Citigroup Eva Fortea-Verdejo - Wells Fargo Robert Burns - H.C. Wainwright Operator Thank you for standing by.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.42 per share a year ago.
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER2+ BTC and multiple ongoing trials in high-value indications. Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for investors.
Zymeworks: Poised For Growth With Platform Validation
Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers.
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Yigal Nochomovitz - Citi Brian Cheng - JPMorgan Jonathan Miller - Evercore ISI Jay Olson - Oppenheimer & Co. Justin Zelin - BTIG Operator Thank you for standing by. This is the conference operator.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz.
